{"id":"pegylated-liposomal-doxorubicin-pld","rwe":[{"pmid":"40605102","year":"2025","title":"Cardiotoxicity of combined pegylated liposomal doxorubicin and bevacizumab therapy: a propensity-matched cohort study and disproportionality analysis.","journal":"Cardio-oncology (London, England)"},{"pmid":"40586926","year":"2025","title":"Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis.","journal":"International journal of clinical oncology"},{"pmid":"40269485","year":"2025","title":"The use of pegylated liposomal doxorubicin in metastatic soft tissue sarcoma.","journal":"Acta oncologica (Stockholm, Sweden)"},{"pmid":"40026872","year":"2025","title":"The Efficacy and Safety of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Children With Osteosarcoma: A Retrospective Real-World Study.","journal":"Cancer innovation"},{"pmid":"39852231","year":"2025","title":"Comparison of Hepatic Function and Chemotherapy-Induced Side Effects Between Pegylated Liposomal Doxorubicin (PLD), Topotecan (TOPO), and Gemcitabine in Platinum-Resistant Ovarian Cancer (PROC).","journal":"Journal of personalized medicine"}],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT02580058","NCT05261490"],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:36:19.705082","allNames":"pegylated liposomal doxorubicin (pld)","offLabel":[],"timeline":[{"date":"2018","type":"neutral","milestone":"Phase 3 Initiated","description":"Phase 3 trial (A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Li) — Ovarian Cancer"},{"date":"2023","type":"negative","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovar) — Ovarian Cancer. Trial terminated early."}],"brandName":"Pegylated Liposomal Doxorubicin (PLD)","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in","explanation":"","oneSentence":"RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"pegylated-liposomal-doxorubicin-pld","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Ovarian Cancer","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"_fixedFields":["pubmed(662)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02580058","phase":"Phase 3","title":"A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Li","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":566,"indication":"Ovarian Cancer","completionDate":"2018-09","primaryEndpoint":"A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall"},{"nctId":"NCT05261490","phase":"Phase 1/2","title":"Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovar","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":10,"indication":"Ovarian Cancer","completionDate":"2023-10","primaryEndpoint":"Pegylated liposomal doxorubicin (PLD), a type of chemotherapy, is a standard treatment option for patients with platinum-resistant ovarian cancer."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL53463"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":662,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","recentPublications":[],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","aiSummary":"Pegylated liposomal doxorubicin (PLD) was a chemotherapy drug developed by Pfizer Inc. that used a liposomal delivery system to encapsulate doxorubicin. The drug's mechanism of action and specific indications are unknown as it was discontinued.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":6,"withResults":3},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}